Aug 25, 2022 7:30 am EDT MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
Aug 11, 2022 4:06 pm EDT MindMed Reports Second Quarter 2022 Financial Results and Business Highlights
Aug 04, 2022 7:30 am EDT MindMed to Host Earnings Call to Discuss Second Quarter 2022 Financial Results and Provide Business Update
Aug 02, 2022 7:30 am EDT MindMed to Participate in the Canaccord Genuity 42nd Annual Growth Conference